Recurrent varicella in an adult psoriasis patient treated with etanercept

Dermatology

Volumn 217, Issue 3, 2008, Pages 260-261

  Becart, S ^a   Segaert, S ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Etanercept; Psoriasis; Tumour necrosis factor ; Varicella

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; ETANERCEPT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; BLOOD EXAMINATION; CASE REPORT; CHICKENPOX; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LETTER; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; SKIN DEFECT;

CHICKENPOX; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE;

EID: 48049112162     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149311     Document Type: Letter

References (14)

1. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van De Kerkhof P, Voorhees J: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151(suppl 69):3-17.
2. Crum NF, Lederman ER, Wallace MR: Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.
3. Carrasco R, Smith JA, Lovell D: Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 2004;6:137-146.
4. Baumgart DC, Dignass AU: Shingles following infliximab infusion. Ann Rheum Dis 2002;61:661.
5. Flendrie M, Vissers WHPM, Creemers MCW, de Jong EMGJ, van de Kerkhof PCM, van Riel PLCM: Dermatologic conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-R676.
6. Lee DH, Kim HS, Song YW, Cho KH: Development of varicella during adalimumab therapy. J Eur Acad Dermatol Venereol 2007;21:687-688.
7. Leung VS, Nguyen MT, Bush TM: Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004;31:2503-2504.
8. Ito M, Nakano T, Kamiya T, Kitamura K, Ihara T, Kamiya H, Sakurai M: Effects of tumor necrosis factor alpha on replication of varicellazoster virus. Antiviral Res 1991;15:183-192.
9. Nikkels AF, Simonart T, Kentos A, Liesnard C, Sadzot-Delvaux C, Feremans W, Piérard GE: Atypical recurrent varicella in 4 patients with hemopathies. J Am Acad Dermatol 2003;48:442-447.
10. Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS: Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999;68:158-161.
11. Vázquez M, Shapiro ED: Varicella vaccine and infection with varicellazoster virus. N Engl J Med 2005;352:439-440.
12. Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
13. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmeter GR, Sterry W, Worm M: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 2007;156:486-491.
14. Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006;213:327-330.